Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the effects of SAR440340/REGN3500 with or without dupilumab, compared to placebo,
on reducing the incidence of "loss of asthma control" (LOAC) events.
Secondary Objectives:
To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340/REGN3500 and
dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1).
To evaluate the effects of coadministration of SAR440340/REGN3500 and dupilumab, compared
with SAR440340 and compared with dupilumab, on FEV1.
To assess safety and tolerability of SAR440340/REGN3500 alone and in coadministration with
dupilumab.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal Fluticasone Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance